Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06700841 In Healthy Subjects And Subjects With Plaque Psoriasis And Bioavailability Of A Tablet Formulation Relative To Suspension Formulation And The Effect Of Food On A Tablet Formulation Of Pf-06700841
Brief Summary: The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).


Options:
A: Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Blood Pressure at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Blood Pressure at Day 28 (Baseline, 16 hours post-dose on Day 28); Single Ascending Dose (SAD) Cohort: Change From Baseline in Pulse Rate at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Pulse Rate at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Pulse Rate at Day 28 (Baseline, 16 hours post-dose on Day 28); Single Ascending Dose (SAD) Cohort: Change From Baseline in Oral Temperature at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Oral Temperature at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Oral Temperature at Day 28 (Baseline, 16 hours post-dose on Day 28); Number of Participants With Change From Baseline in Physical Examinations (SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37); Single Ascending Dose (SAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 28 (Baseline, 16 hours post-dose on Day 28); Single Ascending Dose (SAD) Cohort: Change From Baseline in Heart Rate at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Heart Rate at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Heart Rate at Day 28 (Baseline, 16 hours post-dose on Day 28); Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs (SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37); Number of Adverse Events (AEs) According to Severity (SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37); Number of Participants With Laboratory Abnormalities (SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37); Single Ascending Dose (SAD) Cohort: Change From Baseline in Creatinine Clearance at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28 (Baseline, 16 hours post-dose on Day 28); Food Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1); Food Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841 (pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1); Food Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841 (pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1)
B: Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) (Week 16)
C: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A) (Week 16); Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A) (Week 16)
D: Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1) (Week 12)

Answer: A